Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face

Rosen, Alyx C.; Thimon, S.; Ternant, David; Machet, M.C.; Paintaud, Gilles; Machet, L.

doi:10.1111/j.1365-2133.2010.09803.x

Cited by 27 publications

(15 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several reports suggest that a paclitaxel may be effective in angiosarcomas of the head and the neck. Bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor (VEGF), with or without radiotherapy and chemotherapy, is another viable option; still, further studies are warranted2,9,10,11. VEGF is overexpressed in 80% of angiosarcomas2,10,11.…”

Section: Discussionmentioning

confidence: 99%

A Recurrent Angiosarcoma Isolated to the Eyelid without the Recurrence on the Primary Lesion of the Forehead

Kim

Kang

2014

Ann Dermatol

View full text Add to dashboard Cite

Angiosarcoma is a highly malignant vascular tumor of endothelial origin. Initially, a cutaneous manifestation presents as a singular or multifocal bruise-like patches on the skin, most frequently on the face, the scalp or the neck regions. On progression, the lesions become violaceous, and ill-defined spongy nodular tumors appear. Our patient was a 71-year-old man with a previous history of angiosarcoma on the right forehead and was treated with an excision and local radiation 3 years ago. Several months after the treatment, a dark brownish to violaceous patch with edema arose from the right upper eyelid and spread out to the lower eyelid. Clinically, an ecchymosis caused by trauma or other hemangioma was suspected more than a recurrent angiosarcoma. Histopathologic examinations including immunohistochemical studies were consistent with cutaneous angiosarcoma. Herein, we report a rare case of a recurrent isolated angiosarcoma without the recurrence of a primary lesion.

show abstract

Section: Discussionmentioning

confidence: 99%

A Recurrent Angiosarcoma Isolated to the Eyelid without the Recurrence on the Primary Lesion of the Forehead

Kim

Kang

2014

Ann Dermatol

View full text Add to dashboard Cite

show abstract

“…[18] In one case report, a patient with cutaneous facial angiosarcoma showed partial response to bevacizumab alone. [21] Another case report demonstrated a dramatic response of cutaneous facial angiosarcoma when paclitaxel was combined with bevacizumab. [8] Preoperative radiotherapy and bevacizumab has also been used for angiosarcoma of the head and neck with decent results.…”

Section: Discussionmentioning

confidence: 99%

Primary calvarial angiosarcoma: A case report and review of the literature

Khan

Thakur²,

Ahmed³

et al. 2012

Surg Neurol Int

View full text Add to dashboard Cite

Background:Angiosarcomas are high-grade endothelial tumors remarkable for their rarity and malignant behavior. Primary calvarial angiosarcoma is an extremely rare entity and its behavior usually sets it apart from other angiosarcoma types. We highlight the successful management of cranial angiosarcoma using a multidisciplinary approach.Case Description:We present a 16-year-old male who was first noted to have a right-sided parietal cranial mass that was biopsied in 2008. Pathology was initially thought to be Kaposiform hemangioendothelioma. The patient subsequently underwent chemotherapy with vincristine. The patient did well until early 2010, when he suffered a right-sided intraparenchymal intratumoral hemorrhage. At this time, the original pathologic diagnosis was revisited and the diagnosis was upgraded to an angiosarcoma. The patient underwent a second round of chemotherapy using vincristine, cyclophosphamide, and actinomycin. The tumor continued to progress despite this treatment and he developed extensive skull deformity. At this point more definitive surgical intervention was reconsidered. Preoperative embolization of the mass was performed followed by aggressive surgical resection of the bony disease. The patient tolerated the procedure well and was discharged 6 days postoperatively without any new deficits. The patient is currently in the process of completing radiation therapy to entire tumor bed. He has clinically done well with no neurologic deterioration and has demonstrated long-term survival (>3 years).Conclusion:With the combined efforts of pediatric oncology, radiation oncology, interventional neuroradiology, and neurosurgery, a survival of greater than 3 years is possible with this aggressive pathology.

show abstract

“…Paclitaxel have been shown to produce excellent responses in a number of studies in a variety of anatomic sites [23–28]. New agents against angiogenesis, such as bevacizumab [29–33] or rapamycin [34], might also be useful against this tumor. Study by Sher et al shows a 48% overall response rate to chemotherapy, especially using anthracycline-ifosfamide or gemcitabine-taxane therapies [5].…”

Section: Discussionmentioning

confidence: 99%

Primary Breast Angiosarcoma: Avoiding a Common Trap

Desbiens

Hogue

Lévesque

2011

Case Reports in Oncological Medicine

View full text Add to dashboard Cite

Background. Primary breast angiosarcoma is a rare entity. Case. Initial diagnosis was a benign hemangioma at core biopsy. Wide local excision was performed, with positive margins. Pathology after surgery reported a moderately differentiated angiosarcoma. Tumor was finally treated using mastectomy and radiations. She developed a second angiosarcoma in contralateral breast, with an initial diagnosis on core biopsy of an atypical vascular lesion and was again treated using mastectomy and radiations. She developed bones and lung metastases. Conclusion. Primary breast angiosarcoma is a rare entity often difficult to diagnose on core biopsy, and a benign differential diagnosis is frequent. A highly vascular breast mass should always be considered malignant until proven otherwise. Surgical treatment seems to be the best course of action. There is a lack of data proving efficacy of adjuvant chemotherapy and radiation therapy.

show abstract

Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face

Cited by 27 publications

References 5 publications

A Recurrent Angiosarcoma Isolated to the Eyelid without the Recurrence on the Primary Lesion of the Forehead

A Recurrent Angiosarcoma Isolated to the Eyelid without the Recurrence on the Primary Lesion of the Forehead

Primary calvarial angiosarcoma: A case report and review of the literature

Primary Breast Angiosarcoma: Avoiding a Common Trap

Contact Info

Product

Resources

About